ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
First hospitalised COVID-19 patient dosed in FSD201 treatment trial
December 18, 2020The study will evaluate whether FSD201 is safe and of benefit to hospitalised patients with COVID-19, in combination with standard of care. -
FSD Pharma applies to FDA for trial testing FSD201 in COVID-19 patients
September 03, 2020The Investigational New Drug Application (IND) is for a Phase II trial evaluating the safety and efficacy of FSD201 (ultramicronized PEA) in hospitalised COVID-19 patients. -
FSD Pharma seeks FDA nod for FSD201 phase 2 trial in Covid-19 patients
September 02, 2020FSD Pharma has filed an application with the US Food and Drug Administration (FDA) seeking its approval to launch a phase 2 trial for FSD201 (ultramicronised palmitoylethanolamide, or ultramicronised PEA) in Covid-19 patients.
Pharma Sources Insight January 2025
